Steady-state sVCAM-1 serum levels in adults with sickle cell disease

被引:25
作者
Schnog, JB [1 ]
Rojer, RA
Gillavry, MR
Cate, H
Brandjes, DPM
Duits, AJ
机构
[1] St Elizabeth Hosp, Dept Internal Med, Curacao, Neth Antilles
[2] St Elizabeth Hosp, Red Cross Bloodbank, Curacao, Neth Antilles
[3] Slotervaart Hosp, Dept Internal Med 9B, NL-1066 EC Amsterdam, Netherlands
关键词
sickle cell disease; adhesion molecule; sVCAM-1; severity;
D O I
10.1007/s00277-003-0609-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cytokines and adhesion molecules play an important role in the pathophysiology of vaso-occlusion in sickle cell disease (SCD), and their in vivo profiles are potential tools for assessing SCD severity. We compared steady-state soluble vascular cell adhesion molecule-1 (sVCAM-1) serum levels to clinical (painful crisis frequency, occurrence of acute chest syndrome, leg ulcers, and cerebrovascular disease) and related hematological parameters of SCD severity (such as HbF%, hemoglobin levels, and leukocyte counts) in 29 HbSS adults. Serum sVCAM-1 levels were not related to clinical severity, but an inverse correlation was demonstrated between sVCAM-1 and hemoglobin levels (r=-0.71, p<0.001) with a positive correlation to serum lactate dehydrogenase levels (r=0.59, p=0.008). Based upon these results, steady-state serum sVCAM-1 levels do not seem to reflect clinical disease severity. However, as VCAM-1 is involved in hematopoiesis, sVCAM-1 levels might reflect bone marrow activity in SCD. This underlies the pleiotropic nature of adhesion molecules in vivo and the need for further research in this area, especially since therapies targeting (cellular) adhesive interactions involving the endothelium are emerging for SCD.
引用
收藏
页码:109 / 113
页数:5
相关论文
共 40 条
[1]   Mechanisms of disease - Pathogenesis and treatment of sickle cell disease [J].
Bunn, HF .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) :762-769
[2]   Cytokines and vascular cell adhesion molecule-1 in the blood of patients undergoing HPC mobilization [J].
Dosquet, C ;
Chen, Y ;
Makke, J ;
Miclea, JM ;
Coudert, MC ;
Marolleau, JP ;
Fermand, JP ;
Cottu, P ;
Lotz, JP ;
Benbunan, M .
TRANSFUSION, 2001, 41 (02) :206-212
[3]   Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis [J].
Duits, AJ ;
Pieters, RC ;
Saleh, AW ;
VanRosmalen, E ;
Katerberg, H ;
Berend, K ;
Rojer, RA .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1996, 81 (01) :96-98
[4]   SICKLE RETICULOCYTES ADHERE TO VCAM-1 [J].
GEE, BE ;
PLATT, OS .
BLOOD, 1995, 85 (01) :268-274
[5]   Soluble receptors in human disease [J].
Heaney, ML ;
Golde, DW .
JOURNAL OF LEUKOCYTE BIOLOGY, 1998, 64 (02) :135-146
[6]   ERYTHROCYTE ADHERENCE TO ENDOTHELIUM IN SICKLE-CELL-ANEMIA - A POSSIBLE DETERMINANT OF DISEASE SEVERITY [J].
HEBBEL, RP ;
BOOGAERTS, MAB ;
EATON, JW ;
STEINBERG, MH .
NEW ENGLAND JOURNAL OF MEDICINE, 1980, 302 (18) :992-995
[7]   Pulse oximetry in a cohort study of sickle cell disease [J].
Homi, J ;
Levee, L ;
Higgs, D ;
Thomas, P ;
Serjeant, G .
CLINICAL AND LABORATORY HAEMATOLOGY, 1997, 19 (01) :17-22
[8]  
Jacobsen K, 1996, BLOOD, V87, P73
[9]  
JONECKIS CC, 1993, BLOOD, V82, P3548
[10]   Monoclonal antibodies to αVβ3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor [J].
Kaul, DK ;
Tsai, HM ;
Liu, XD ;
Nakada, MT ;
Nagel, RL ;
Coller, BS .
BLOOD, 2000, 95 (02) :368-374